Announced
Completed
Financials
Tags
manufacture
pharmaceuticals
innovative specialty services
development of speciality medicine
Biotechnology
pharmaceuticals manufacturing
Pharmaceuticals
United Kingdom
Public
Scheme
Friendly
Single Bidder
Acquisition
Domestic
Majority
Failed
Synopsis
AbbVie, an American pharmaceutical company headquartered in North Chicago, Illinois, failed to acquire Shire, a UK-founded Jersey-registered specialty biopharmaceutical company, for $55bn. "AbbVie has built a strong, sustainable strategy with a robust pipeline. Over the past 22 months we have delivered industry leading stockholder returns, our performance and business fundamentals remain strong, and we are on the cusp of a major new product launch with our treatment for HCV. We remain focused on building AbbVie’s business through enhanced internal R&D platforms, partnerships, strong commercial execution and licensing and acquisitions," Richard A. Gonzalez, AbbVie Chairman and CEO.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.